Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15492721 | 0.84 | KDM4E (0.62) | ACACBMTNR1AMTNR1BHPGDKDM4E | |
| SCHEMBL19002635 | 0.84 | HPGD (0.46) | HPGDKDM4EF13A1HSD17B10SMN1; SMN2 | |
| SCHEMBL19001320 | 0.82 | ACACB (0.48) | ACACBMTNR1AMTNR1BHPGDSMN1; SMN2 | |
| SCHEMBL19002285 | 0.81 | ACACB (0.51) | ACACBMTNR1AMTNR1BKDM4EMEN1 | |
| SCHEMBL18997759 | 0.80 | POLB (0.48) | ACACBHPGDKDM4EF13A1HSD17B10 | |
| SCHEMBL7842536 | 0.78 | KDM4E (0.68) | ACACBMTNR1AMTNR1BHPGDKDM4E | |
| SCHEMBL19001318 | 0.77 | MTNR1A (0.54) | ACACBMTNR1AMTNR1BHPGDKDM4E | |
| Bromide SCHEMBL29990070 | 0.77 | KDM4E (0.66) | ACACBMTNR1AMTNR1BHPGDKDM4E | |
| SCHEMBL12313357 | 0.75 | HDAC2 (0.56) | MTNR1AMTNR1BSMN1; SMN2MEN1MAPT | |
| SCHEMBL19001316 | 0.75 | ACACB (0.48) | ACACBMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | ACACB 807/4885MTNR1A 1704/4885MTNR1B 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.